Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) has entered a strategic partnership with Shanghai RAAS Blood Products Co., Ltd. (SHE: 002252) to develop novel subcutaneous formulations of blood products utilizing recombinant human hyaluronidase (rHuPH20) technology. The collaboration aims to transform hours-long intravenous infusions into minutes-long subcutaneous injections, addressing critical patient compliance and healthcare efficiency challenges in the $30 billion global blood products market.
Partnership Structure
Element
Detail
Companies
Shanghai Bao Pharmaceuticals (2659.HK) × Shanghai RAAS (SZ.002252)
Technology
rHuPH20 (recombinant human hyaluronidase) subcutaneous delivery
Target Products
Novel blood product formulations
Core Innovation
Overcoming traditional 2mL subcutaneous volume limitation
Capability
Enabling subcutaneous delivery of hundreds of milliliters
Value Proposition
IV-to-SC conversion: hours → minutes administration time
Mechanism: rHuPH20 temporarily depolymerizes hyaluronan in subcutaneous tissue, increasing permeability and enabling rapid dispersion and absorption of large-volume biologics and blood products
Strategic Rationale & Market Context
Factor
Strategic Implication
Blood Products Market
Global market >$30 billion; immunoglobulins (IVIG) represent largest segment with growing SC substitution trend
Combine RAAS blood fractionation expertise with Bao delivery technology
2026-2027
Regulatory Pathway
NMPA IND submissions for lead candidates
2027-2028
Manufacturing Scale
Joint capacity planning for subcutaneous blood product production
2028-2029
Market Launch
China commercialization with potential global licensing
2029+
Patient-Centric Value: Partnership aims to deliver “more convenient and patient-friendly” therapies, addressing quality-of-life deficits in chronic blood product-dependent conditions (primary immunodeficiency, hemophilia, CIDP).
Resource Optimization: Shift from clinic-based IV administration to home-based SC therapy aligns with China’s healthcare cost containment and tertiary hospital decongestion policy priorities.
Forward‑Looking Statements This brief contains forward‑looking statements regarding subcutaneous blood product development timelines, regulatory approval pathways, and commercial potential of rHuPH20-enabled formulations. Actual results may differ due to formulation stability challenges, immunogenicity risks with hyaluronidase, and competitive responses from global blood product leaders (CSL Behring, Takeda, Grifols).-Fineline Info & Tech
By Fineline Cube 